211 related articles for article (PubMed ID: 28686654)
1. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
Cassim H; Otwombe K; Lazarus E; Liberty A; Gray GE; Greeff OBW; Violari A
PLoS One; 2017; 12(7):e0180645. PubMed ID: 28686654
[TBL] [Abstract][Full Text] [Related]
2. First-line antiretroviral drug discontinuations in children.
Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
4. Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis.
Technau KG; Schomaker M; Kuhn L; Moultrie H; Coovadia A; Eley B; Rabie H; Wood R; Cox V; Vizcaya LS; Muchiri E; Davies MA;
Pediatr Infect Dis J; 2014 Jun; 33(6):617-22. PubMed ID: 24378944
[TBL] [Abstract][Full Text] [Related]
5. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T
AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331
[TBL] [Abstract][Full Text] [Related]
6. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.
Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V
J Int AIDS Soc; 2017 Apr; 20(1):21362. PubMed ID: 28453240
[TBL] [Abstract][Full Text] [Related]
7. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.
Technau KG; Lazarus E; Kuhn L; Abrams EJ; Sorour G; Strehlau R; Reubenson G; Davies MA; Coovadia A
Pediatr Infect Dis J; 2013 Aug; 32(8):851-5. PubMed ID: 23860481
[TBL] [Abstract][Full Text] [Related]
8. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.
Meyers TM; Yotebieng M; Kuhn L; Moultrie H
Pediatr Infect Dis J; 2011 Nov; 30(11):974-9. PubMed ID: 21734620
[TBL] [Abstract][Full Text] [Related]
11. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus.
Shiau S; Arpadi S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L
J Pediatr; 2013 Jun; 162(6):1138-45, 1145.e1-2. PubMed ID: 23312691
[TBL] [Abstract][Full Text] [Related]
12. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa.
Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP
Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449
[TBL] [Abstract][Full Text] [Related]
13. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
Musiime V; Cook A; Kayiwa J; Zangata D; Nansubuga C; Arach B; Kenny J; Wavamunno P; Komunyena J; Kabamba D; Asiimwe AR; Mirembe G; Abongomera G; Mulenga V; Kekitiinwa A; Kityo C; Walker SA; Klein N; Gibb DM;
Antivir Ther; 2014; 19(3):269-76. PubMed ID: 24717427
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
[TBL] [Abstract][Full Text] [Related]
15. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
16. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.
Strehlau R; Shiau S; Arpadi S; Patel F; Pinillos F; Tsai WY; Coovadia A; Abrams E; Kuhn L
J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e70-e77. PubMed ID: 29373687
[TBL] [Abstract][Full Text] [Related]
17. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.
Shlay JC; Sharma S; Peng G; Gibert CL; Grunfeld C
J Acquir Immune Defic Syndr; 2008 May; 48(1):53-62. PubMed ID: 18491421
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
Galizzi N; Galli L; Poli A; Gianotti N; Carini E; Bigoloni A; Tambussi G; Nozza S; Lazzarin A; Castagna A; Mancusi D; Termini R
PLoS One; 2018; 13(2):e0191300. PubMed ID: 29451870
[TBL] [Abstract][Full Text] [Related]
20. Once vs twice-daily abacavir and lamivudine in African children.
Musiime V; Kasirye P; Naidoo-James B; Nahirya-Ntege P; Mhute T; Cook A; Mugarura L; Munjoma M; Thoofer NK; Ndashimye E; Nankya I; Spyer MJ; Thomason MJ; Snowden W; Gibb DM; Walker AS;
AIDS; 2016 Jul; 30(11):1761-70. PubMed ID: 27064996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
